Your session is about to expire
← Back to Search
N/A
Helmet NIV for COVID-19 Respiratory Failure
N/A
Recruiting
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Positive End Expiratory Pressure (PEEP) level between 8 to 13cm H20
Adequate gag and cough reflex
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
Study Summary
This trial will test whether or not a helmet-based ventilation system can help reduce the amount of time patients with COVID-19 need to be on a ventilator.
Who is the study for?
This trial is for adults over 18 who've been on mechanical ventilation for at least 48 hours due to acute respiratory failure, including COVID-19. They must be able to breathe on their own and have stable blood pressure without heavy reliance on medications. Pregnant individuals, those with severe brain injury or coma, or anyone refusing intubation are excluded.Check my eligibility
What is being tested?
The study tests if helmet non-invasive ventilation (NIV) can reduce the time patients need invasive mechanical breathing support during illnesses like COVID-19 by allowing earlier removal from ventilators while still supporting their breathing needs.See study design
What are the potential side effects?
While not explicitly stated here, potential side effects of helmet NIV may include discomfort wearing the device, skin breakdown around the neck area where it seals, dryness of mouth or throat, and possibly claustrophobia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My breathing support is set to a specific pressure level.
Select...
I can swallow and cough normally.
Select...
I am 18 or older and have been on a ventilator for at least 48 hours.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
ventilator days
Secondary outcome measures
Intensive care unit (ICU) length of stay
need for re-intubation
Other outcome measures
ICU related complications
diaphragm thickening fraction
diaphragm ultrasound thickness
+5 moreTrial Design
2Treatment groups
Active Control
Group I: Helmet non invasive ventilation (NIV)Active Control1 Intervention
Patients randomized to the intervention group will be extubated to helmet NIV.
Group II: Control invasive mechanical ventilationActive Control1 Intervention
Patients randomized to the control group will continue invasive mechanical ventilation. Once weaning criteria are met, patients will undergo a spontaneous breathing trial for 30 minutes. If the spontaneous breathing trial is successful, then the patient will be extubated.
Find a Location
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,004 Previous Clinical Trials
819,669 Total Patients Enrolled
Media Library
Research Study Groups:
This trial has the following groups:- Group 1: Helmet non invasive ventilation (NIV)
- Group 2: Control invasive mechanical ventilation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger